Investigation of Japanese encephalitis virus as a cause of acute encephalitis in southern Pakistan, April 2015-January 2018.
Acute Disease
Adolescent
Adult
Aged
Antibodies, Neutralizing
/ blood
Antibodies, Viral
/ immunology
Child
Child, Preschool
Cross Reactions
Encephalitis Virus, Japanese
/ immunology
Encephalitis, Viral
/ diagnosis
Humans
Immunoglobulin M
/ blood
Infant
Male
Middle Aged
Pakistan
/ epidemiology
Young Adult
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
16
02
2020
accepted:
28
05
2020
entrez:
13
6
2020
pubmed:
13
6
2020
medline:
29
8
2020
Statut:
epublish
Résumé
Japanese encephalitis (JE) occurs in fewer than 1% of JE virus (JEV) infections, often with catastrophic sequelae including death and neuropsychiatric disability. JEV transmission in Pakistan was documented in 1980s and 1990s, but recent evidence is lacking. Our objective was to investigate JEV as a cause of acute encephalitis in Pakistan. Persons aged ≥1 month with possible JE admitted to two acute care hospitals in Karachi, Pakistan from April 2015 to January 2018 were enrolled. Cerebrospinal fluid (CSF) or serum samples were tested for JEV immunoglobulin M (IgM) using the InBios JE DetectTM assay. Positive or equivocal samples had confirmatory testing using plaque reduction neutralization tests. Among 227 patients, testing was performed on CSF in 174 (77%) and on serum in 53 (23%) patients. Six of eight patient samples positive or equivocal for JEV IgM had sufficient volume for confirmatory testing. One patient had evidence of recent West Nile virus (WNV) neurologic infection based on CSF testing. One patient each had recent dengue virus (DENV) infection and WNV infection based on serum results. Recent flavivirus infections were identified in two persons, one each based on CSF and serum results. Specific flaviviruses could not be identified due to serologic cross-reactivity. For the sixth person, JEV neutralizing antibodies were confirmed in CSF but there was insufficient volume for further testing. Hospital-based JE surveillance in Karachi, Pakistan could not confirm or exclude local JEV transmission. Nonetheless, Pakistan remains at risk for JE due to presence of the mosquito vector, amplifying hosts, and rice irrigation. Laboratory surveillance for JE should continue among persons with acute encephalitis. However, in view of serological cross-reactivity, confirmatory testing of JE IgM positive samples at a reference laboratory is essential.
Sections du résumé
BACKGROUND
Japanese encephalitis (JE) occurs in fewer than 1% of JE virus (JEV) infections, often with catastrophic sequelae including death and neuropsychiatric disability. JEV transmission in Pakistan was documented in 1980s and 1990s, but recent evidence is lacking. Our objective was to investigate JEV as a cause of acute encephalitis in Pakistan.
METHODS
Persons aged ≥1 month with possible JE admitted to two acute care hospitals in Karachi, Pakistan from April 2015 to January 2018 were enrolled. Cerebrospinal fluid (CSF) or serum samples were tested for JEV immunoglobulin M (IgM) using the InBios JE DetectTM assay. Positive or equivocal samples had confirmatory testing using plaque reduction neutralization tests.
RESULTS
Among 227 patients, testing was performed on CSF in 174 (77%) and on serum in 53 (23%) patients. Six of eight patient samples positive or equivocal for JEV IgM had sufficient volume for confirmatory testing. One patient had evidence of recent West Nile virus (WNV) neurologic infection based on CSF testing. One patient each had recent dengue virus (DENV) infection and WNV infection based on serum results. Recent flavivirus infections were identified in two persons, one each based on CSF and serum results. Specific flaviviruses could not be identified due to serologic cross-reactivity. For the sixth person, JEV neutralizing antibodies were confirmed in CSF but there was insufficient volume for further testing.
CONCLUSIONS
Hospital-based JE surveillance in Karachi, Pakistan could not confirm or exclude local JEV transmission. Nonetheless, Pakistan remains at risk for JE due to presence of the mosquito vector, amplifying hosts, and rice irrigation. Laboratory surveillance for JE should continue among persons with acute encephalitis. However, in view of serological cross-reactivity, confirmatory testing of JE IgM positive samples at a reference laboratory is essential.
Identifiants
pubmed: 32530966
doi: 10.1371/journal.pone.0234584
pii: PONE-D-20-04498
pmc: PMC7292402
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Immunoglobulin M
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0234584Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Travel Med. 2018 May 1;25(suppl_1):S16-S26
pubmed: 29718435
Microbiol Immunol. 1994;38(10):827-30
pubmed: 7869964
Am J Trop Med Hyg. 2016 Apr;94(4):820-828
pubmed: 26856911
Emerg Infect Dis. 2009 Oct;15(10):1691-2
pubmed: 19861079
Emerg Infect Dis. 2011 May;17(5):934-6
pubmed: 21529419
Lancet. 2008 Feb 9;371(9611):500-9
pubmed: 18262042
Int J Infect Dis. 2019 Apr;81:137-139
pubmed: 30664985
J Clin Microbiol. 2000 May;38(5):1823-6
pubmed: 10790107
J Med Virol. 1988 Nov;26(3):243-7
pubmed: 2849632
Indian J Pediatr. 2004 Jul;71(7):609-15
pubmed: 15280610
N Engl J Med. 2006 Aug 31;355(9):869-71
pubmed: 16943399
Acta Trop. 2018 Dec;188:108-117
pubmed: 30118701
J Clin Microbiol. 1976 Dec;4(6):503-10
pubmed: 1002829
Acta Trop. 2018 Jul;183:84-91
pubmed: 29625090
Clin Vaccine Immunol. 2007 Sep;14(9):1084-93
pubmed: 17609393
N Engl J Med. 2004 Jul 22;351(4):370-8
pubmed: 15269317
Wkly Epidemiol Rec. 2015 Feb 27;90(9):69-87
pubmed: 25726573
Expert Rev Anti Infect Ther. 2014 Aug;12(8):901-4
pubmed: 24927959
Lancet Infect Dis. 2018 Nov;18(11):e355-e361
pubmed: 29934112
MMWR Morb Mortal Wkly Rep. 2017 Jun 09;66(22):579-583
pubmed: 28594790
N Engl J Med. 2018 Aug 9;379(6):557-566
pubmed: 30089069
Front Public Health. 2018 Feb 27;6:20
pubmed: 29535994
Nat Med. 2004 Dec;10(12 Suppl):S98-109
pubmed: 15577938
Clin Vaccine Immunol. 2009 Jul;16(7):1052-9
pubmed: 19458204
Int J Infect Dis. 2020 Jun;95:444-456
pubmed: 32205287
Bull World Health Organ. 2011 Oct 1;89(10):766-74, 774A-774E
pubmed: 22084515
Acta Trop. 2005 Jul;95(1):40-57
pubmed: 15878762
PLoS One. 2018 Mar 23;13(3):e0194412
pubmed: 29570739